Rationale for Prostate-Specific-Membrane-Antigen-Targeted Radionuclide Theranostic Applied to Metastatic Clear Cell Renal Carcinoma

Prostate-specific membrane antigen (PSMA), whose high expression has been demonstrated in metastatic aggressive prostate adenocarcinoma, is also highly expressed in the neovessels of various solid tumors, including clear cell renal cell carcinoma (ccRCC). In the VISION phase III clinical trial, PSMA-targeted radioligand therapy (PRLT) with lutetium 177 demonstrated a 4-month overall survival OS benefit compared to the best standard of care in heavily pretreated metastatic prostate cancer. Despite the improvement in the management of metastatic clear cell renal cell carcinoma (mccRCC) with antiangiogenic tyrosine kinase inhibitor (TKI) and immunotherapy, there is still a need for new treatments for patients who progress despite these drugs. In this study, we discuss the rationale of PRLT applied to the treavtment of mccRCC.

Automated summary

PSMA, highly expressed in metastatic aggressive prostate adenocarcinoma and neovessels of solid tumors, demonstrated an overall survival benefit in heavily pretreated metastatic prostate cancer in the VISION phase III trial. Despite advancements in managing metastatic clear cell renal cell carcinoma with antiangiogenic tyrosine kinase inhibitors and immunotherapy, there is still a need for new treatments. This study discusses the rationale of PSMA-targeted radioligand therapy in the treatment of metastatic clear cell renal cell carcinoma.